Abstract
WWP1 E3 ubiquitin ligase has previously been shown to be frequently amplified and overexpressed in prostate and breast cancers. However, the mechanism of WWP1 action is still largely unknown. p63, a member of the p53 family of transcription factors, has an important function in tumor development by regulating apoptosis. Using alternative promoters, p63 can be expressed as ΔNp63 and TAp63. Increasing evidence suggests that TAp63 sensitizes cells to apoptosis but ΔNp63 has an opposite function. In this study, we show that WWP1 binds, ubiquitinates, and destructs both ΔNp63α and TAp63α. The protein–protein interaction occurs between the PY motif of p63 and the WW domains of WWP1. The knockdown of WWP1 by siRNA increases the endogenous ΔNp63α level in the MCF10A and 184B5 immortalized breast epithelial cell lines and confers resistance to doxorubicin-induced apoptosis. On the other hand, the knockdown of WWP1 increases the endogenous level of TAp63α, induces apoptosis, and increases sensitivity to doxorubicin and cisplatin in the HCT116 colon cancer cell line in a p53-independent manner. Finally, we found that DNA damage chemotherapeutic drugs induce WWP1 mRNA and protein expression in a p53-dependent manner. These data suggest that WWP1 may have a context-dependent role in regulating cell survival through targeting different p63 proteins for degradation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- Ab:
-
antibody
- CHX:
-
cycloheximide
- Cpt:
-
cisplatin
- DBD:
-
DNA-binding domain
- ER:
-
estrogen receptor
- HECT:
-
homologous to the E6-associated protein carboxyl terminus
- GST:
-
glutathione S-transferase
- IP:
-
immunoprecipitation
- RACK1:
-
receptor of activated protein C kinase
- SCC:
-
squamous cell carcinoma
- TA:
-
transactivation
- WT:
-
wild type
- WWP1:
-
WW domain-containing E3 ubiquitin protein ligase 1
References
Chen C, Matesic LE . The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 2007; 26: 587–604.
Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W et al. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 2007; 26: 2386–2394.
Chen C, Zhou Z, Ross JS, Zhou W, Dong JT . The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 2007; 121: 2834–2841.
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128: 129–139.
Suzuki A, Shibata T, Shimada Y, Murakami Y, Horii A, Shiratori K et al. Identification of SMURF1 as a possible target for 7q21.3–22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization. Cancer Sci 2008; 99: 986–994.
Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002; 62: 7162–7165.
Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K et al. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 2004; 23: 6914–6923.
Seo SR, Lallemand F, Ferrand N, Pessah M, L’Hoste S, Camonis J et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 2004; 23: 3780–3792.
Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A . Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 2005; 280: 22115–22123.
Shaye DD, Greenwald I . LIN-12/Notch trafficking and regulation of DSL ligand activity during vulval induction in Caenorhabditis elegans. Development 2005; 132: 5081–5092.
Shen R, Chen M, Wang YJ, Kaneki H, Xing L, O’Keefe R J et al. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 2006; 281: 3569–3576.
Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 2005; 280: 41553–41561.
Laine A, Ronai Z . Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007; 26: 1477–1483
Yang A, McKeon F . P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1: 199–207.
Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63: 2351–2357.
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305–316.
Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714–718.
Senoo M, Pinto F, Crum CP, McKeon F . p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129: 523–536.
Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8: 551–561.
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW . The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370–1380.
Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97: 5462–5467.
Watson IR, Irwin MS . Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 2006; 8: 655–666.
Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T et al. RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2004; 3: 1285–1295.
Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 2006; 103: 12753–12758.
Bakkers J, Camacho-Carvajal M, Nowak M, Kramer C, Danger B, Hammerschmidt M . Destabilization of DeltaNp63alpha by Nedd4-mediated ubiquitination and Ubc9-mediated sumoylation, and its implications on dorsoventral patterning of the zebrafish embryo. Cell Cycle 2005; 4: 790–800.
Hansen TM, Rossi M, Roperch JP, Ansell K, Simpson K, Taylor D et al. Itch inhibition regulates chemosensitivity in vitro. Biochem Biophys Res Commun 2007; 361: 33–36.
Sayan BS, Sayan AE, Yang AL, Aqeilan RI, Candi E, Cohen GM et al. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc Natl Acad Sci USA 2007; 104: 10871–10876.
Swaroop M, Sun Y . Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth. Anticancer Res 2003; 23: 3167–3174.
Liu W, Zhang R . Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol 1998; 12: 793–804.
Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769–1775.
Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25: 1054–1060.
Koker MM, Kleer CG . p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004; 28: 1506–1512.
Rossi M, De Simone M, Pollice A, Santoro R, La Mantia G, Guerrini L et al. Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle 2006; 5: 1816–1822.
Nguyen Huu N, Ryder W, Zeps N, Flasza M, Chiu M, Hanby A et al. Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. J Pathol 2008; 216: 93–102.
Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW . p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45–56.
Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA . Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004; 114: 2063–2072.
Barbieri CE, Pietenpol JA . p63 and epithelial biology. Exp Cell Res 2006; 312: 695–706.
Helton ES, Zhu J, Chen X . The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 2006; 281: 2533–2542.
Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161: 1199–1206.
Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113–7121.
Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005; 24: 836–848.
Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR . p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 18: 126–131.
Chen C, Bhalala HV, Qiao H, Dong JT . A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002; 21: 6567–6572.
Chen C, Bhalala HV, Vessella RL, Dong JT . KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003; 55: 81–88.
Acknowledgements
This study was supported in part by a grant from American Cancer Society, A grant from The Department Of Defense Prostate Cancer Research Program (W81XWH-07-1-0191), and a Grant (BCTR0503705) from the Susan G Komen Breast Cancer Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by G Melino
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Rights and permissions
About this article
Cite this article
Li, Y., Zhou, Z. & Chen, C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15, 1941–1951 (2008). https://doi.org/10.1038/cdd.2008.134
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/cdd.2008.134
Keywords
This article is cited by
-
Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α
Cell Death & Differentiation (2024)
-
The role of NEDD4 related HECT-type E3 ubiquitin ligases in defective autophagy in cancer cells: molecular mechanisms and therapeutic perspectives
Molecular Medicine (2023)
-
WWP1 E3 ligase at the crossroads of health and disease
Cell Death & Disease (2023)
-
The role of ubiquitin signaling pathway on liver regeneration in rats
Molecular and Cellular Biochemistry (2023)
-
Clinical significance of FBXW7 loss of function in human cancers
Molecular Cancer (2022)
